Effects of zinc, vitamin D, and their co-supplementation on mood, serum cortisol, and brain-derived neurotrophic factor in patients with obesity and mild to moderate depressive symptoms:A phase II, 12-wk, 2 × 2 factorial design, double-blind, randomized, placebo-controlled trial by Yosaee, Somaye et al.
 
 
Effects of zinc, vitamin D, and their co-
supplementation on mood, serum 
cortisol, and brain-derived 
neurotrophic factor in patients with 
obesity and mild to moderate 
depressive symptoms: A phase II, 12-
wk, 2 × 2 factorial design, double-blind, 
randomized, placebo-controlled trial 
Yosaee, S, soltani, S, Esteghamati, A, Motevalian, A, Tehrani-
Doost, M, Clark, C & Jazayeri, S 
Author post-print (accepted) deposited by Coventry University’s Repository 
 
Original citation & hyperlink:  
Yosaee, S, soltani, S, Esteghamati, A, Motevalian, A, Tehrani-Doost, M, Clark, C & 
Jazayeri, S 2020, 'Effects of zinc, vitamin D, and their co-supplementation on mood, 
serum cortisol, and brain-derived neurotrophic factor in patients with obesity and 
mild to moderate depressive symptoms: A phase II, 12-wk, 2 × 2 factorial design, 









NOTICE: this is the author’s version of a work that was accepted for publication in 
Nutrition. Changes resulting from the publishing process, such as peer review, 
editing, corrections, structural formatting, and other quality control mechanisms 
may not be reflected in this document. Changes may have been made to this work 
since it was submitted for publication. A definitive version was subsequently 
published in Nutrition, 71, (2019) DOI: 10.1016/j.nut.2019.110601 
 
© 2019, Elsevier. Licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International 
http://creativecommons.org/licenses/by-nc-nd/4.0/10.1016/j.nut.2019.110601 
 
Copyright © and Moral Rights are retained by the author(s) and/ or other copyright 
owners. A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. This item cannot be reproduced or quoted extensively 
 
 
from without first obtaining permission in writing from the copyright holder(s). The 
content must not be changed in any way or sold commercially in any format or medium 
without the formal permission of the copyright holders.  
 
This document is the author’s post-print version, incorporating any revisions agreed during 
the peer-review process. Some differences between the published version and this version 




Effects of zinc, vitamin D and their co-supplementation on mood, serum cortisol, and 1 
brain-derived neurotrophic factor in patients with obesity and mild to moderate 2 
depressive symptoms: A 12-week, 2× 2 factorial design, double-blind, randomized, 3 
placebo-controlled trial  4 
Keywords: depression, obesity, BDNF, cortisol 5 
Somaye Yosaee1,2,3, Sepideh Soltani4,5, Alireza Esteghamati6, Abbas Motevalian7, Mehdi 6 
 Tehrani-Doost8, Cain C. T. Clark9, Shima Jazayeri1,10*  7 
  8 
1 Department of Nutrition, School of Public Health, Iran University of Medical 7 9 
 Sciences,Tehran, Iran  10 
  2Department of Nutrition, School of Health, Larestan University of Medical Sciences,  11 
 Larestan, Iran  12 
 3 Department of Nutrition, Emam Reza Teaching Hospital, Larestan University of Medical  13 
 Sciences, Larestan, Iran  14 
 4Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical  15 
 Sciences, Yazd, Iran  16 
 5Yazd Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, 16 17 
 Yazd, Iran  18 
 6Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran  19 
 University of Medical Sciences, Tehran, Iran.  20 
 7Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, 21 
Tehran, Iran  22 
 8Department of Psychiatry School of Medicine, Roozbeh Psychiatry Hospital Tehran  23 
2 
 
 University of Medical Sciences, Tehran, Iran. 24 
 9Centre for Sport, Exercise and Life Sciences, Coventry University, CV1 5FB, U.K.  25 
 10Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology & 26 





1. Introduction:  30 
Mood disorders, particularly depression, are one of the most prevalent mental health symptoms 31 
in patients with obesity (1-3). Several studies have reported that patients with obesity can suffer 32 
with major depression (4-6). Although the direction of the association between depression and 33 
obesity has been questioned (3, 7, 8), the co-occurrence of both may have a detrimental 34 
synergistic effect on overall health and treatment response (9). A growing evidence base 35 
indicates that there are abnormalities in the hypothalamic-pituitary-adrenal axis, particularly in 36 
the regulation of cortisol, in clinically depressed patients, which is, in turn, related to obesity 37 
(10-12). Moreover, empirical evidence has suggested that Brain-derived neurotrophic factor 38 
(BDNF), a homo-dimer protein, has a critical role in the pathophysiology of depression (13).  39 
Despite representing the most preponderant treatment for depression, antidepressant 40 
medications have been reported to show resistance in depression associated with obesity (14, 41 
15), whilst remission is only achieved in one-third of the patients after treatment with 42 
antidepressant agents (16). Furthermore, pharmacotherapy is usually costly (16-18). The 43 
expense and incongruent effectiveness in patients with obesity highlights the need to 44 
investigate alternative preventive and treatment approaches to traditional antidepressant 45 
medication. In recent years, it has been shown that nutritional intervention can be considered 46 
as an effective alternative or adjunct, preventive or treatment strategy to pharmacotherapy in 47 
depression (19). In particular, Zinc and vitamin D have been well linked with the treatment or 48 
management of depression (20-23). 49 
Zinc deficiency can induce depressive-like behavior, and in this instance, the symptom can be 50 
effectively reversed by zinc supplementation (24, 25). Zinc may produce antidepressant-like 51 
effects by modulating the functions of the hypothalamus–pituitary–adrenal (HPA) axis and 52 
increasing serum BDNF (13, 26-28). Moreover, there is wealth of literature suggesting zinc 53 
supplementation is an effective adjunct therapy for major depressive disorders (13, 29, 30). 54 
Similar to zinc, inadequate vitamin D intake has been associated with depression (31, 32); 55 
whilst it has also been demonstrated that multiple brain regions are associated with depressive 56 
disorders, including the prefrontal cortex and hippocampus, and possess specific nuclear 57 
receptors for 1,25(OH)D (32, 33). 58 
Although there have been significant advances in understanding the potential role of zinc and 59 
vitamin D in depression (13, 23), the literature, particularly in regard to vitamin D, is equivocal 60 
(34-36). Whilst, to date, only one randomized control trial has examined the effects of zinc 61 
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monotherapy on BDI-II score in obese patients, which resulted in a decreased BDI-II score 62 
(13). In addition, only one study has examined the effects of vitamin D monotherapy on BDI- 63 
II in obese patients with pre-existing depressive symptoms, where the authors suggested that 64 
supplementation of high doses of vitamin D can ameliorate depression symptoms (23). 65 
However, the results other studies investigating the effect of vitamin D supplementation on 66 
depression are divergent (37-39), and may be mediated by the inconsistent doses and duration 67 
of vitamin D supplementation. 68 
Several meta-analyses have evaluated effect of zinc/vitamin D on depression (40-43) , 69 
concluding that, although there is evidence supporting their use, available research needs to be 70 
confirmed by larger RCT and prospective cohort studies (44-46). Furthermore, the effects of 71 
vitamin D or zinc on depression have mostly been explored independently in previous studies 72 
(13, 23), and to the author’s knowledge, no study has examined the effects of zinc- vitamin D 73 
co-supplementation on depression symptoms in obese subjects. Interestingly, there is evidence 74 
to suggest that zinc homeostasis and function may be increased following vitamin D 75 
supplementation, and that the control of zinc in systemic levels is regulated by vitamin D (47). 76 
The current trial hypothesized that there may be additive benefits from combining zinc and 77 
vitamin D. Thus, the present study sought to investigate the effects of zinc, vitamin D, and their 78 
combination, on depression score, serum BDNF, and cortisol level in obese patients with mild 79 
to moderate depression.  80 
2. Material& method 81 
2.1. participants 82 
The present study was a 12-week 2 × 2 factorial design randomized double-blind placebo 83 
controlled trial, and was conducted among 140 overweight/obese (BMI> 27 kg/m2) adult 84 
subjects aged > 20 years with BDI-II≥10. Obese/overweight subjects were recruited from 85 
patients who were referred to the Endocrinology and Metabolism Research Center (EMRC), 86 
Vali-Asr, Emam khomeini Hospital in Tehran, Iran between July 2016 and February 2017. The 87 
depression status was evaluated by Beck Depression Inventory-II (BDI-II) questionnaire, and 88 
those who had a BDI-II score greater than 10 points were considered as eligible for current the 89 
trial. We excluded patients who had a history of psychiatric and neurological disorders (such 90 
as schizophrenia Parkinson’s, Alzheimer’s disease, anxiety, suicidal thoughts), coronary artery 91 
disease, acute or chronic renal failure, acute or chronic hepatic failure, chronic inflammatory 92 
and autoimmune disease, or any known malignancy, had been received antidepressant 93 
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medicines (in the preceding 3 months), or steroid or hormone-therapy. Other non-pathological 94 
exclusion criteria included pregnancy, breastfeeding, post-menopause, smoking, professional 95 
athlete, uncontrolled thyroid disorder, >3 kg weight change during the last 3 months, use of 96 
medications for dyslipidemia or hypertension, hypnotics, sedatives and immunosuppressive, 97 
any kind of supplements or following a special diet prescribed by the clinic dietitian. It was 98 
explained to each participant that the dose and type of supplement(s) assigned must not be 99 
changed during the intervention period, or they would be excluded from the study. 100 
2.2. Ethics statements 101 
This trial was performed according to the principles of the Declaration of Helsinki, and the 102 
study protocol was approved by the institutional ethics committee of Iran University of Medical 103 
Sciences (IR.IUMS.REC 1395.9221324205). The study protocol was carefully explained to all 104 
subjects signing an informed consent form. This trial was registered in the Iranian Web site 105 
(www.irct.ir) for registration of clinical trials (http://www.irct.ir: IRCT201601252394N31- 31- 106 
10-2016). The project was financially supported by Iran University of Medical Sciences.   107 
2.3. Study design and intervention  108 
Randomized assignment was performed using balanced the block randomization method. 109 
Block randomization works by randomizing participants within blocks such that an equal 110 
number are assigned to each treatment arm. Block randomization is a commonly used 111 
technique in trials with small sample sizes (48). In the present trial, the block size was 8. 112 
Participants were initially randomized to ‘intervention vs Placebo,’ and then assigned to one 113 
of the four groups via the balanced block randomization method (in a 1:1:1:1 ratio), (1) subjects 114 
received 2000 IU vitamin D3 daily plus a daily placebo for zinc; 2) subjects received 30 mg 115 
zinc gluconate per day plus a daily placebo for vitamin D; 3) subjects received 2000 IU vitamin 116 
D3 daily plus 30 mg zinc gluconate per day; or 4) subjects received identical matching placebos 117 
for vitamin D and zinc for 12 weeks. At the beginning of the study, participants were requested 118 
not to change their routine lifestyle throughout the study and not to consume any supplements 119 
or medication other than that provided to them by the investigators. The doses of vitamin D3 120 
and zinc were chosen after a comprehensive review of the available literature to achieve 121 
optimal efficacy and safety (13, 49). The appearance of the placebo was indistinguishable in 122 
color, shape, size, packaging, and taste from vitamin D and zinc tablets. The zinc supplements 123 
were tablets manufactured by the Jalinus Pharmaceutical Company (Tabriz, Iran) and the 124 
placebo (made from starch) was provided by the School of Pharmacy, Tehran University of 125 
Medical Sciences. The vitamin D supplements and placebos (made from starch) were tablets 126 
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manufactured by Pars mino Company (Tehran, Iran). All research staff including investigators 127 
and laboratory technicians, as well as participants, were blinded to the random allocation. 128 
2.4. Treatment adherence 129 
The tablets were supplied to the participants, fortnightly, by the trial staff. Each bottle contained 130 
15 tablets, and a tablet count was performed fortnightly by the investigator to assess 131 
compliance. To increase the adherence, all participants received short messages on their cell 132 
phones to take the supplements every day. 133 
2.5. Assessment of variables 134 
All assessments and measurements were made at study baseline and after the intervention 135 
period. Weight (in kilograms −kg) was measured using a calibrated Seca scale (Model 700, 136 
USA) with participants in light clothing and unshod. Standing height was measured to nearest 137 
1 cm using a Seca stadiometer (Model 700, USA) while subjects were unshod. Body mass 138 
index (BMI) of each participant was calculated as body weight divided by height squared 139 
(kg/m2). Waist circumference was measured using a flexible tape at the smallest circumference 140 
around coastal margin. A professional nurse measured the systolic and diastolic blood pressure 141 
on the non-dominant brachial artery, with the participants in a seated position, after having 142 
rested at least for 10 minutes. Blood pressure was measured twice, and the average of 2 143 
measurements was considered as the final systolic and diastolic blood pressure. A trained 144 
researcher completed questionnaires on participants socio-demographic background and 145 
physical activity, whilst a researcher provided a comprehensive explanation of how to complete 146 
the self-rating BDI-II questionnaire. The trial used the validated Persian version of Beck 147 
depression inventory-II (BDI-II) (50)  148 
 149 
To assess serum 25(OH) D, zinc, BDNF and cortisol levels, blood samples (10 cc) were 150 
obtained after a 12-hour overnight fast at study baseline (week 0) and after intervention (week 151 
12). All blood samples were centrifuged at 3000g for 10 minutes, the serum was separated into 152 
clean tube aliquots, and were stored at -80˚C until analysis at the Iran University of Medical 153 
Sciences Reference Laboratory. Serum 25(OH)D concentrations were quantified using the 154 
enzyme-linked immunosorbent assay (ELISA) method (Euroimmun,). The inter- and intra- 155 
assay coefficients of variation of this method were 8.6% and 3.2%. respectively. A serum 156 
25(OH) D level <75 nmol/l (<30 ng/ml) was considered insufficient. ELISA methods were 157 
used to measure serum cortisol (diametra, Italy). The inter- and intra-assay coefficients of 158 
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variation of this method were 11% and 5.1%. respectively. Serum BDNF was quantified using 159 
the ELISA method (crystalday, china). The inter- and intra-assay coefficients of variation of 160 
this method were 10% and 8% respectively. 161 
2.6. Sample size 162 
 163 
To calculate sample size, we used the standard formula suggested for factorial design, clinical 164 
trials by considering type I error (a) of 0.05 and type II error (b) of 0.20. Based on a previous 165 
study (13), we used 5.698 as the standard deviation and 2.92 as the mean difference in BDI-II 166 
score as a variable primary outcome. Based on this, we required 33 persons in each group. 167 
Accounting for 2 dropouts (effect size: 0.52) in each group, the final sample size was 168 
determined to be 35 persons per group. 169 
2.7. Statistical methods 170 
 171 
We evaluated changes in depression symptoms as a primary outcome, during an average of 12 172 
weeks of follow-up, in those randomized to zinc-vitamin D and their combined 173 
supplementation compared to placebo. The Kolmogorov–Smirnov test was used to examine 174 
and confirm the normal distribution of variables. The analyses were performed based on a per- 175 
protocol approach. One-way analysis of variance (ANOVA) was used to detect differences in 176 
general characteristics, blood pressure and anthropometric measurement, at the study baseline 177 
and post-intervention between the groups. To estimate the effect of zinc, vitamin D and their 178 
combination on outcomes, we first computed the changes from baseline by subtracting the 179 
baseline value from the end-of-trial value, and then applied analysis of co-variance (ANCOVA; 180 
adjusted by baseline serum zinc, vitamin D, cortisol, BDNF and beck depression score). To 181 
ensure that baseline characteristics balance was achieved by the randomization, analyses was 182 
conducted for baseline characteristics (zinc, vitamin D, age, sex, BMI, weight, height). In cases 183 
of minor imbalances, adjustment for these variables will be made our analyses. For all tests, 184 
statistical significance was accepted at p≤0.05. All analyses were performed using the 185 
Statistical Package for Social Sciences version 21 (SPSS, Chicago, IL, USA). 186 
3.Results: 187 
The present study was conducted using 140 obese patients with mild to moderate depression. 188 
In total, 15 patients declined to complete the intervention, and were therefore excluded from 189 
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subsequent analysis (diagram 1). Dropout rate was not significant between the treatment arms 190 
(P= 0.785). Serum levels and tablet counts of zinc and vitamin D at the end of the intervention 191 
suggested that the compliance was excellent. No significant differences in demographic 192 
characteristics were observed among the 4 intervention arms at baseline. Moreover, there was 193 
no significant difference in anthropometric measurements, such as weight, BMI, waist 194 
circumference (WC) and blood pressure, in zinc, vitamin D and co-supplementation groups 195 
compared to placebo (p>0.05). We found a significant decrease in blood pressure among those 196 
who received vitamin D (systolic blood pressure: 121.61±13.81 vs 118.00±15.76, P=0.0001. 197 
diastolic blood pressure: 81.96±10.00 vs 84.58±9.79, P=0.014) or joint zinc–vitamin D 198 
(systolic blood pressure: 119.26±14.07 vs 114.73±14.66, P=0.0001. diastolic blood pressure: 199 
80.30±10.80 vs 78.73±11.94, P=0.0001) supplements. A significant decrease in WC was 200 
shown in vitamin D (106.91±11.39 vs 105.33±11.69, P=0.0001), zinc (103.63±5.84 vs 201 
103.14±6.38, P=0.0001) and combined zinc–vitamin D (105.25±8.95 vs 103.85±9.20, 202 
P=0.0001) groups. The baseline and post-intervention characteristics of the study population 203 
are presented in Table 1. There was no evidence that supplementation elicited any injurious or 204 
negative side effect(s). 205 
The effects of vitamin D, zinc and combined zinc–vitamin D supplementation on BDI-II, serum 206 
cortisol and BDNF are detailed in Table 2. No significant differences in BDI-II score were 207 
observed among the 4 intervention arms at baseline. The baseline mean of the BDI-II score 208 
was 19.21±7.34, for the whole population. All subjects had BDI-II≥10 at baseline, and after 12 209 
weeks intervention, 45.2%, 66.7%, 59.4%, and 86.2% of participants in zinc, vitamin D, zinc- 210 
vitamin D and placebo groups, respectively. had BDI-II≥10. Zinc, vitamin D, and their co- 211 
supplementation yielded a significant reduction in depression score (p<0.0001). However, a 212 
greater reduction in depression score was observed in the zinc group compared with vitamin D 213 
group (p<0.001). No significant changes in BDI-II score were observed in placebo group 214 
(p=0.396).  215 
We found significant differences in serum zinc (p<0.001), vitamin D (table 3) (p<0.001), 216 
cortisol (p=0.049) and BDNF (p=0.004) (table 2) between the study groups at baseline. The 217 
baseline mean of BDNF, cortisol, zinc, and 25-(OH) D levels were 2.54±1.61ng/ml, 218 
16.52±5.87 ng/ml, 74.85±36.36mg/dl, and 18.99±12.02ng/ml respectively, for the whole 219 
sample population. We found a significant increase in serum zinc, and 25-(OH) D levels among 220 
those who received zinc, vitamin D or joint zinc–vitamin D supplements. However serum 25- 221 
(OH) D levels was also significantly reduced in the placebo group (p< 0.001). 222 
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Zinc, vitamin D or zinc+vitamin D had no significant effects on serum cortisol level. There 223 
was a significant decrease in serum BDNF levels in the zinc (p=0.035) and placebo (p=0.016) 224 
groups, respectively; whilst there was no significant change in the vitamin D group. 225 
4.Discussion: 226 
In the present study, we found that 3 months of supplementation with 30 mg/day of zinc 227 
gluconate, and 2000 IU vitamin D, either individually or in combination, significantly 228 
improved depression status compared to placebo in obese subjects who had BDI-II≥10. 229 
However, among these participants we found that, monotherapy with 30 mg zinc gluconate 230 
outperformed 2000 IU vitamin D in improving the depression-related symptoms over 12 weeks 231 
of follow-up. There was no significant differences in BDI-II score among the 4 intervention 232 
arms at baseline. Our results suggest that depressed patients could take zinc, vitamin D, either 233 
individually or concurrently, to improve mood and depression severity. Previous studies have 234 
shown that vitamin D or zinc supplementation, individually, may improve depression severity 235 
(13, 23), although this has been disputed in some empirical work (34-36). 236 
Although favorable effects from zinc supplementation on depression-related symptoms have 237 
been demonstrated in previous clinical trials (13, 51, 52), some work has reported that there is 238 
no evidence for the significant association between zinc and depression (34). Importantly, it 239 
should be noted that the aforementioned clinical trials were generally conducted in people who 240 
were not affected by obesity. Thus, the role of supplemental zinc in obese patients with 241 
depression remains controversial. One meta-analysis showed that zinc concentrations were 242 
approximately −1.85mmol/L lower in depressed subjects vs. control subjects (46). Similarly, 243 
Zongyao Li noted a significant inverse association between dietary zinc intake and risk of 244 
depression (44). The current trial suggests a causal association between zinc status and 245 
depression in obese/overweight subjects, and that greater depression improvement is manifest 246 
in zinc, compared to vitamin D, supplementation.  247 
In the present study, we found that vitamin D elicited a favorable effect on depression scores 248 
in overweight/obese subjects. Findings in some earlier clinical trials regarding the effect of 249 
vitamin D supplementation on depression have been inconsistent (23, 35, 53). A large 250 
randomized trial in older women assessed the effect of a single annual dose of 500 kIU vitamin 251 
D for 3–5 y, and did not find any effect of vitamin D supplementation on depression symptom 252 
(35); whilst further work reported that weekly supplementation with 40000 IU vitamin D for 6 253 
months had no significant effect on depressive symptom scores, when compared with placebo 254 
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(54). A recent meta-analysis, which included nine trials with a total of 4923 participants, 255 
concluded that no significant reduction in depression was seen after vitamin D supplementation 256 
(45). In a double-blinded, placebo controlled prospective trial, involving 489 postmenopausal 257 
elderly women, there was no effect of hormone therapy and calcitriol, either individually or in 258 
combination, on depression (55). Supplementation with 400 IU of vitamin D combined with 259 
1,000 mg of elemental calcium on measures of depression in a randomized, double-blinded US 260 
trial comprising 36,282 postmenopausal women did not affect depression symptoms (56). 261 
However, contrastingly, some studies have reported a beneficial effect of vitamin D 262 
supplementation on depression (23). For instance, a trial conducted in elderly patients with 263 
MDD showed that a single 300-kIU dose of vitamin D results in a decreased score of depression 264 
(57); whilst in a study of 441 obese subjects, it was indicated that supplementation with 20.000 265 
or 40.000 IU vitamin D per week for 1 year ameliorates depression symptoms (23). Congruent 266 
with previous meta-analyses (58, 59), and a RCT study (23), our study found a significant 267 
reduction in depressive symptoms after 3 months vitamin D supplementation. It is possible that 268 
vitamin D is clinically beneficial for individuals who are depressed, but not in healthy 269 
participants; thus, variability in depression stage could be considered as an explanatory factor 270 
for this finding, but clearly necessitates further investigation. In the current trial, zinc 271 
supplementation outperformed vitamin D for improving depression score.   272 
Several biological mechanisms for the beneficial effects of zinc and vitamin D on depression 273 
have been proposed (44, 60). ‘Neurotrophin hypothesis of depression’, mainly based on the 274 
inverse association between stress and brain-derived neurotrophic factor (BDNF) levels, is one 275 
of the most popular hypotheses in the pathophysiology of depression (61). Expression of BDNF 276 
has been reported to be down-regulated in depressed patients, compared to non-depressed 277 
matched controls (62), however, it is shown to increase after chronic antidepressant 278 
administration (62). In Solati, et al., zinc supplementation resulted in increased serum BDNF 279 
levels (13). However, in the present study, after 12 weeks of treatment with zinc, serum levels 280 
of BDNF dropped significantly compared to baseline, but were not statistically different as 281 
compared to the placebo group. This may conceivably be related to a placebo effect, because 282 
the placebo group had a significant reduction in levels of BDNF, while no concurrent reduction 283 
in depression was noted. In addition, the regression to mean phenomenon, where if a variable 284 
is extreme on its first measurement, it will tend to be closer to the average on its second 285 
measurement—and if it is extreme on its second measurement, it will tend to have been closer 286 
to the average on its first, may be considered as an alternative explanation for the changes in 287 
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BDNF in the zinc and placebo groups. At baseline, the zinc group had a significantly higher 288 
level of serum BDNF compare to all other groups. In Ranjbar et al, it was reported that serum 289 
levels of BDNF in depressed patients receiving zinc supplement did not increase (51). In the 290 
present study, to the best of our knowledge, we are the first to report vitamin D and joint zinc- 291 
vitamin D supplementation has no effect on serum BDNF. 292 
Other mechanisms have been proposed to mediate the effects of zinc and vitamin D on 293 
depression, including modulation of the hypothalamus–pituitary–adrenal (HPA) axis (63). Zinc 294 
and vitamin D, an anti-inflammatory element, help to maintain endocrine homeostasis and 295 
regulation of the hippocampal and cortical glutamatergic circuits that subserve affective 296 
regulation and cognitive function (64, 65). However, in the current trial, serum levels of cortisol 297 
in obese patients with depression receiving zinc, vitamin D or their co-supplementation were 298 
not decreased. Several hypotheses exist to explain why no beneficial effects of zinc-vitamin D 299 
joint supplementation, compared to zinc or vitamin D individually, reduced depression related 300 
symptom. The dose of vitamin D we tested (2000 IU/day) may not have been sufficient to 301 
affect the depression score in obese patients. Participants in our study were obese individuals 302 
with MDD, who might have an increased need to vitamin D. In addition, normal status in zinc 303 
at baseline and continuity of vitamin D deficiency at study cessation in the zinc-vitamin D 304 
group could explain this finding.  305 
The current trial has several strengths. Mood disorders, particularly depression, are among the 306 
leading causes of morbidity in obese subjects (4, 5). Current modalities for treatment of 307 
depression are insufficient and expensive (15, 16), and the prevalence of zinc and vitamin D 308 
insufficiency is high (66, 67). Furthermore, our study was conducted on patients with 309 
depressive symptoms with limited physical activity levels and sun exposure, which, in turn, 310 
would contribute to vitamin D insufficiency (53). This study highlights the need for adequately 311 
powered randomized clinical trials to establish whether there is a causal relation between zinc, 312 
vitamin D status and depression severity in overweight/obese subjects. We believe that this 313 
study is the first clinical trial to quantitatively evaluate the joint effects of zinc and vitamin D 314 
monotherapy on serum BDNF, cortisol levels and depression severity in overweight/obese 315 
subjects with depressive symptoms. In light of the current evidence represents a valuable 316 
addition to the current findings on the efficacy of zinc and vitamin D monotherapy on 317 
depression symptoms.  318 
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However, there are some limitations to the present RCT which must be considered. Firstly, the 319 
study population was comprised of obese/overweight subjects with BDI-II≥10 who received 320 
zinc, vitamin D supplementation in the absence of anti-depressant medications, thus, these 321 
findings may not be generalizable to severely depressed subjects already prescribed anti- 322 
depressant medications. Second, our sample size calculation was based on the variability in 323 
depression score, and may not have been adequate for the analysis of serum cortisol as a 324 
secondary outcome. Third, serum cortisol levels were reported in this trial, however, it is 325 
arguable that urine measurement is the preferred method for cortisol assessment. Furthermore, 326 
daily physiological and behavioral rhythms including sleep, and body temperature can 327 
significantly influence cortisol concentration, which we could not control in the present study. 328 
Finally, in the current trial, despite the randomization, serum zinc and vitamin D level at 329 
baseline were unequal, however, these variables were adjusted accordingly in the applied 330 
analysis. 331 
Supplementation with zinc, vitamin D or joint zinc–vitamin D can improve BDI-II score in 332 
obese patients with depressive symptoms. However, the zinc, vitamin D and depression 333 
improvements appear to be independent from serum cortisol and BDNF. To confirm the 334 
veracity of the findings of present trial, further trials with longer durations and larger sample 335 
sizes are needed. 336 
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Table 1: characterization of participants at baseline and after 12 week 562 
 Zinc (n=24) Vitamin D (n=27) Zinc-vitaminD (n=25) Placebo (n=22) P-valueǂ 




Baseline 121.20±12.72 121.61±13.81 119.26±14.07 116.79±11.75 0.625 
After 12 
week 
117.40±11.28 118.00±15.76 114.73±14.66 118.17±12.58 0.790 








80.68±7.91 84.58±9.79 80.30±10.80 80.21±6.07 0.882 
81.55±7.48 81.96±10.00 78.73±11.94 79.08±10.92 0.127 
0.055 0.014 <0.0001 0.212  
Weight 
(Kg) 
Baseline 86.40±10.13 90.42±16.51 86.31±14.36 87.20±12.86 0.625 
After 12 
week 
86.62±9.89 90.61±16.01 85.42±14.88 87.67±12.62 0.493 
 P-valueƗ  0.884 0.636 0.284 0.770  
       
BMI(kg/
m2) 
Baseline  29.08±2.96 30.59±4.08 29.59±3.64 30.11±3.68 0.428 
After 12 
week 
29.14±2.99 30.63±3.93 29.38±3.48 30.13±3.73 0.373 
      
 P-valueƗ  0.866 0.717 0.154 0.850  
       








103.63±5.84 106.91±11.39 105.25±8.95 103.84±8.58 0.513 
103.14±6.38 105.33±11.69 103.85±9.20 104.43±9.53 0.846 
<0.0001 <0.0001 <0.0001 <0.0001  
Note: BMI=Body Mass Index 563 
ǂ: Values are analyzed by one-way analysis of variance; Ɨ: Values are analyzed by paired-samples T test 564 






Table 2: change in BDI-II, serum BDNF and cortisol level from baseline to 12 weeks 569 




Placebo (mean) (95% 
CI) 
P-value ǂ ß 
BDI-II score -7.02 (-9.13, -4.74) -3.87 (-6.15, -1.59) -7.62 (-10.63, -4.61) -0.76 (-3.05, 1.52) 0.0001* 0.969 
BDNF -0.19 (-0.36, -0.02) -0.11 (-0.28, 0.05) 0.19 (-0.02, 0.41) -0.17 (-0.34, -0.003) 0.08 0.589 
Cortisol -1.37 (-3.43, 0.67) -1.66 (-3.71, 0.38) -0.82 (-3.52. 1.88) -1.19 (-3.29, 0.90) 0.974 0.056 
BDI-II: Beck Depression Score-II 570 
ǂ: Values are analyzed by ANCOVA (adjusted by baseline serum zinc, vitamin D, cortisol and BDNF and beck depression score);  571 
*Significant differences between zinc and placebo groups, vitamin D and placebo groups, zinc-vitamin D and placebo groups, zinc and vitamin D groups 572 
values are mean ± SD 573 
  574 
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Table 3: serum zinc, vitamin D, cortisol and BDNF, at baseline and after 12 week base on study groups. 575 
 576 
 Zinc Vitamin D Zinc-vitamin D Placebo P-valueǂ ß 
Zinc µg/dl Baseline  57.13±21.91 60.25±17.74 115.37±22.45 62.48±19.01 >0.001*  
After 12 week 77.03±47.26 58.60±13.30 127.90±38.65 56.80±14.36 >0.001** 0.969 
 P-valueƗ  0.008 0.588 0.068 0.213   
Vitamin D 
ng/ml 
Baseline  15.86±9.03 26.07±13.27 10.44±5.23 20.51±10.43 >0.001***  
After 12 week 14.00±8.06 36.29±11.28 17.93±7.28 16.85±10.07 >0.001**** 1.000 
P-valueƗ  0.141 >0.001 >0.001 >0.001   
ǂ: Values are analyzed by ANCOVA (adjusted by baseline serum zinc, vitamin D); Ɨ: Values are analyzed by paired-samples T test 577 
*Significan differences between zinc-vitamin D and placebo groups, zinc-vitamin D and zinc groups, zinc-vitamin D and vitamin D groups 578 
** Significan differences between zinc-vitamin D and placebo groups, zinc-vitamin D and vitamin D groups, zinc and placebo groups, zinc and vitamin D groups. 579 
*** significant differences between vitamin D and zinc groups, zinc- vitamin D and placebo groups, zinc- vitamin D and vitamin D groups. 580 
**** significant differences between zinc-vitamin D and vitamin D groups, zinc-vitamin D and placebo groups, zinc-vitamin D and zinc groups, vitamin D and zinc groups, vitamin D 581 
and placebo groups. 582 
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Flow diagram1: depicting progress through different phases of the clinical trial 
Assessed for eligibility (n=415) 
Excluded (n= 275) 
  Not meeting inclusion criteria (n=165 ) 
  Declined to participate (n=110) 
Analysed (n=32) 
 
Lost to follow-up (n=3) 
Unwilling to countine (n=2) 
Pregnancy (n=1) 
Allocated to intervention (n=35) 
 Received allocated intervention 
(n=35) 
Lost to follow-up (n=4) 
Unwilling to countine (n= 3) 









Allocated to intervention (n=35) 
 Received allocated intervention 
(n=35) 
 
Allocated to intervention (n=35) 
 Received allocated intervention 
(n=35) 
 
Allocated to intervention (n=35) 
 Received allocated intervention 
(n=35) 
 
Zinc and vitamin D supplement Zinc and vitamin D placebo Zinc placebo & vitamin D placebo Vitamin D and zinc placebo 
Lost to follow-up (n=6) 
Unwilling to countine (n= 6) 
Lost to follow-up (n=2) 
Unwilling to countine (n= 2) 
 
Analysed (n=33) 
 
 
Analysed (n=29) 
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